Atricure Inc. Stock
?
Your prediction
Financial data and news for AtriCure
sharewise wants to provide you with the best news and tools for AtriCure, so we directly link to the best financial data sources.
Financials
News
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure is targeting $1 billion in revenue by 2030, after reporting roughly 18% five-year compound growth, a 77%
AtriCure Q2 Earnings Call Highlights
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure posted strong Q2 2026 results, with revenue up 12.8% to $153.6 million and a return to GAAP
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
Maggie Yuen, a director at AtriCure, Inc. (NASDAQ:ATRC), reported a sale of 3,500 shares of common stock on August 5, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Karen Prange, a director of the company, sold 23,325 shares of common stock in AtriCure, Inc. (NASDAQ:ATRC) on August 5, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the